Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$5.95
+3.8%
$6.91
$3.80
$10.90
$24.40M-0.916,262 shs1,664 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19170,086 shs4.12 million shs
Marpai, Inc. stock logo
MRAI
Marpai
$1.35
-2.2%
$1.27
$0.40
$1.68
$22.32M4.6818,523 shs951 shs
Psychemedics Corporation stock logo
PMD
Psychemedics
$2.67
$2.52
$1.50
$3.25
N/AN/A35,163 shs113,627 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00%+7.46%-20.25%+39.98%-38.75%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+10.54%-68.45%
Marpai, Inc. stock logo
MRAI
Marpai
0.00%0.00%0.00%+40.63%+87.47%
Psychemedics Corporation stock logo
PMD
Psychemedics
0.00%0.00%0.00%0.00%+14.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.8438 of 5 stars
0.05.00.00.00.01.70.6
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/AN/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
0.00
N/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$383.96M0.07N/AN/A$51.05 per share0.12
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Marpai, Inc. stock logo
MRAI
Marpai
$34.87M0.64N/AN/A($1.72) per share-0.78
Psychemedics Corporation stock logo
PMD
Psychemedics
$19.68M0.83N/AN/A$0.84 per share3.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$42.23MN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Marpai, Inc. stock logo
MRAI
Marpai
-$28.75M-$1.82N/AN/A-85.70%N/A-100.23%8/5/2025 (Estimated)
Psychemedics Corporation stock logo
PMD
Psychemedics
-$1.86M-$0.510.00N/A-9.26%-32.32%-18.53%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/A
Psychemedics Corporation stock logo
PMD
Psychemedics
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.67
0.46
0.45
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Marpai, Inc. stock logo
MRAI
Marpai
N/A
0.82
0.82
Psychemedics Corporation stock logo
PMD
Psychemedics
0.01
1.82
1.82

Institutional Ownership

CompanyInstitutional Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Marpai, Inc. stock logo
MRAI
Marpai
49.75%
Psychemedics Corporation stock logo
PMD
Psychemedics
32.07%

Insider Ownership

CompanyInsider Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Marpai, Inc. stock logo
MRAI
Marpai
61.30%
Psychemedics Corporation stock logo
PMD
Psychemedics
13.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Marpai, Inc. stock logo
MRAI
Marpai
15016.53 million5.61 millionNo Data
Psychemedics Corporation stock logo
PMD
Psychemedics
1406.11 million5.26 millionNot Optionable

Recent News About These Companies

Psychemedics Releases 2025 Workforce Insights Report
Phoenix Molecular Designs Launches Phase II Trial in RSK2-High Breast Cancer
Psychemedics announces reverse stock split, forward stock split
Psychemedics reminds stockholders to cast votes for Annual Meeting
Psychemedics Reports Improved Losses Amid Revenue Dip
Psychemedics Corporation (PMD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$5.95 +0.22 (+3.82%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Marpai stock logo

Marpai NASDAQ:MRAI

$1.35 -0.03 (-2.17%)
As of 07/3/2025 12:17 PM Eastern

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.

Psychemedics stock logo

Psychemedics NASDAQ:PMD

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.